Inovio Pharmaceuticals, Inc. Share Price

Equities

INO

US45773H4092

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
10.57 USD +4.40% Intraday chart for Inovio Pharmaceuticals, Inc. +9.19% +72.71%
Sales 2024 * 604K 48.37M Sales 2025 * 8.03M 643M Capitalization 274M 21.92B
Net income 2024 * -99M -7.93B Net income 2025 * -93M -7.44B EV / Sales 2024 * 453 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 34.1 x
P/E ratio 2024 *
-2.74 x
P/E ratio 2025 *
-3.5 x
Employees 122
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.51%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.40%
1 week+9.19%
Current month-23.85%
1 month-18.88%
3 months+71.87%
6 months+139.75%
Current year+72.71%
More quotes
1 week
9.29
Extreme 9.285
10.82
1 month
8.35
Extreme 8.35
14.75
Current year
4.73
Extreme 4.73
14.75
1 year
3.89
Extreme 3.888
14.75
3 years
3.89
Extreme 3.888
123.96
5 years
3.89
Extreme 3.888
405.48
10 years
3.89
Extreme 3.888
405.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 24/03/19
Director of Finance/CFO 60 31/05/02
Chief Tech/Sci/R&D Officer - 31/01/07
Members of the board TitleAgeSince
Chairman 79 30/11/03
Director/Board Member 64 31/12/17
Director/Board Member 66 14/01/20
More insiders
Date Price Change Volume
26/04/24 10.57 +4.40% 196,113
25/04/24 10.12 -0.34% 154,741
24/04/24 10.16 -2.03% 246,812
23/04/24 10.37 +3.49% 242,734
22/04/24 10.02 +3.51% 335,745

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
10.57 USD
Average target price
19.25 USD
Spread / Average Target
+82.12%
Consensus